Company intelligence / Profile preview
MeiraGTx
London, United Kingdommeiragtx.com ↗
- Ownership
- Public · MGTX
- Employees
- ~350
- Development stage
- Phase 3
01
Overview
MeiraGTx has a broad pipeline with four late-stage clinical programs targeting inherited retinal diseases, large degenerative eye conditions, neurodegenerative disorders like Parkinson's disease (with a pivotal Phase 3 trial planned), and severe xerostomia. Their riboswitch technology enables dose-responsive control of gene therapies using oral small molecules. Clinical data show significant improvements in symptoms for their lead Parkinson's program compared to controls[6]. The company also supports its pipeline with fully integrated GMP manufacturing capabilities across multiple global sites[2][4][5].
- Therapeutic areas
- OphthalmologyOncologyImmunologyNeurology
- Modalities
- Gene therapy (AAV-based)Cell therapy (including CAR-T)Regulated gene expression via riboswitches and oral small molecules
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Hologen Ltd. joint venture for AI-driven optimization of the AAV-GAD/Parkinson's program[6].Other partners not explicitly listed.
04
Financials
- Market cap
- $817.3M
- Total revenue
- $81.4M
- Enterprise value
- $786.5M
Beyond the preview
Go deeper on MeiraGTx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MeiraGTx.